The project is being led by the Monash Institute of Pharmaceutical Sciences (MIPS) in partnership with long term collaborator, Seaport Therapeutics, and is being backed by up to AUD$21.5M via the ARPA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results